Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $87,025.96 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $0.98, for a total value of $87,025.96. Following the completion of the transaction, the insider owned 5,168,303 shares of the company’s stock, valued at approximately $5,064,936.94. The trade was a 1.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Tuesday, November 25th, Bioventures 2014 L.P. Mpm sold 42,533 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.92, for a total value of $39,130.36.
• On Friday, November 21st, Bioventures 2014 L.P. Mpm sold 64,331 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total value of $53,394.73.
• On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $36,625.28.
• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $62,344.56.
• On Tuesday, November 18th, Bioventures 2014 L.P. Mpm sold 52,627 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $48,943.11.
• On Monday, November 17th, Bioventures 2014 L.P. Mpm sold 57,061 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total transaction of $54,207.95.
• On Friday, November 14th, Bioventures 2014 L.P. Mpm sold 61,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $57,325.20.
• On Thursday, November 13th, Bioventures 2014 L.P. Mpm sold 90,951 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $89,131.98.
• On Wednesday, November 12th, Bioventures 2014 L.P. Mpm sold 40,669 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total value of $44,329.21.
• On Tuesday, November 11th, Bioventures 2014 L.P. Mpm sold 55,810 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $63,623.40.

Werewolf Therapeutics Stock Performance

Shares of HOWL traded down $0.07 during trading hours on Tuesday, reaching $0.91. 461,162 shares of the company’s stock traded hands, compared to its average volume of 505,004. The firm has a market capitalization of $44.19 million, a price-to-earnings ratio of -0.56 and a beta of 0.73. The business’s fifty day simple moving average is $1.52 and its two-hundred day simple moving average is $1.34. Werewolf Therapeutics, Inc. has a twelve month low of $0.60 and a twelve month high of $2.38. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. Analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities reduced their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Bank of America dropped their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Finally, Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quadrature Capital Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter worth $28,000. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics during the second quarter valued at approximately $48,000. Nuveen LLC acquired a new position in Werewolf Therapeutics in the 1st quarter valued at approximately $71,000. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics in the 1st quarter valued at approximately $79,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $92,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.